Big Pharma Split (TSX:PRM.PR.A.PFD) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Big Pharma Split Debt-to-Equity?

Big Pharma Split's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. Big Pharma Split's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. Big Pharma Split's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$15.85 Mil. Big Pharma Split's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Big Pharma Split's Debt-to-Equity or its related term are showing as below:

TSX:PRM.PR.A.PFD's Debt-to-Equity is not ranked ^*
in the Asset Management industry.
Industry Median: 0.19
* Ranked among companies with meaningful Debt-to-Equity only.

Big Pharma Split Debt-to-Equity Historical Data

The historical data trend for Big Pharma Split's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Big Pharma Split Debt-to-Equity Chart

Big Pharma Split Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

Big Pharma Split Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial								-	-	-	-	-

Competitive Comparison of Big Pharma Split's Debt-to-Equity

For the Asset Management subindustry, Big Pharma Split's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Big Pharma Split's Debt-to-Equity Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, Big Pharma Split's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Big Pharma Split's Debt-to-Equity falls into.

Big Pharma Split Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Big Pharma Split's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	15.851
	=	0.00

Big Pharma Split's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	15.851
	=	0.00

Big Pharma Split (TSX:PRM.PR.A.PFD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Big Pharma Split Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Big Pharma Split's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Big Pharma Split (TSX:PRM.PR.A.PFD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » Big Pharma Split Corp (TSX:PRM.PR.A.PFD) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

PRM:Canada

Address

610 Chartwell Road, Suite 204, Oakville, ON, CAN, L6J 4A5

Website

https://www.harvestportfolios.com

Big Pharma Split Corp is a mutual fund corporation. Its investment objective is to provide shareholders with fixed cumulative preferential quarterly cash distributions, and regular monthly cash distributions. The company has a presence in the United States; Switzerland; France and United Kingdom.

Big Pharma Split (TSX:PRM.PR.A.PFD) Headlines

No Headlines